• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Sonographic evaluation of vascular normalization induced by lenvatinib in a patient with hepatocellular carcinoma.

作者信息

Takahashi Hiroshi, Sugimoto Katsutoshi, Kamiyama Naohisa, Kakegawa Tatsuya, Wada Takuya, Takeuchi Hirohito, Itoi Takao

机构信息

Department of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishi-Shinjuku, Shinjuku, Tokyo, 160-0023, Japan.

Ultrasound General Imaging, GE HealthCare, Tokyo, Japan.

出版信息

J Med Ultrason (2001). 2025 May 12. doi: 10.1007/s10396-025-01550-3.

DOI:10.1007/s10396-025-01550-3
PMID:40353929
Abstract
摘要

相似文献

1
Sonographic evaluation of vascular normalization induced by lenvatinib in a patient with hepatocellular carcinoma.乐伐替尼诱导肝细胞癌患者血管正常化的超声评估
J Med Ultrason (2001). 2025 May 12. doi: 10.1007/s10396-025-01550-3.
2
The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors.抗血管生成药物仑伐替尼诱导肝癌肿瘤血管正常化并增强放射敏感性。
Med Oncol. 2021 Apr 21;38(6):60. doi: 10.1007/s12032-021-01503-z.
3
Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRβ complex in hepatocellular carcinoma.仑伐替尼通过 NRP-1-PDGFRβ 复合物促进血管正常化，提高抗 PD-1 治疗疗效在肝细胞癌中的作用。
Front Immunol. 2023 Jul 21;14:1212577. doi: 10.3389/fimmu.2023.1212577. eCollection 2023.
4
Noninvasive Visualization of Tumor Blood Vessels within Hepatocellular Carcinoma by Application of Superb Microvascular Imaging to Contrast-Enhanced Ultrasonography.通过将超微血管成像应用于超声造影对肝细胞癌内肿瘤血管进行无创可视化
Diagnostics (Basel). 2024 Mar 23;14(7):678. doi: 10.3390/diagnostics14070678.
5
Vascular Normalization Caused by Short-Term Lenvatinib Could Enhance Transarterial Chemoembolization in Hepatocellular Carcinoma.短期仑伐替尼治疗导致的血管正常化可增强肝癌的经肝动脉化疗栓塞术。
Curr Oncol. 2023 May 5;30(5):4779-4786. doi: 10.3390/curroncol30050360.
6
The Impact of Lenvatinib on Tumor Blood Vessel Shrinkage of Hepatocellular Carcinoma during Treatment: An Imaging-Based Analysis.仑伐替尼治疗肝细胞癌过程中对肿瘤血管收缩的影响：基于影像学的分析。
Oncology. 2023;101(2):134-144. doi: 10.1159/000526976. Epub 2022 Sep 14.
7
Colitis induced by Lenvatinib in a patient with advanced hepatocellular carcinoma.乐伐替尼致晚期肝细胞癌患者结肠炎。
Clin J Gastroenterol. 2021 Feb;14(1):187-192. doi: 10.1007/s12328-020-01249-7. Epub 2020 Oct 6.
8
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.乐伐替尼对比索拉非尼用于不可切除肝细胞癌的一线治疗：来自一项随机、开放标签、非劣效、III 期临床试验的患者报告结局。
Lancet Gastroenterol Hepatol. 2021 Aug;6(8):649-658. doi: 10.1016/S2468-1253(21)00110-2. Epub 2021 Jun 2.
9
Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib.经动脉化疗栓塞联合 PD-1 抑制剂加仑伐替尼治疗不可切除肝细胞癌的疗效优于 PD-1 抑制剂加仑伐替尼。
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231166765. doi: 10.1177/15330338231166765.
10
Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma.与甲状腺癌和肝细胞癌患者接受仑伐替尼治疗的依从性相关的因素。
PLoS One. 2023 Nov 16;18(11):e0294320. doi: 10.1371/journal.pone.0294320. eCollection 2023.

本文引用的文献

1
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial.一项关于经动脉化疗栓塞疗法联合乐伐替尼治疗不可切除中期肝细胞癌的2期前瞻性多中心单臂试验：TACTICS-L试验
Liver Cancer. 2023 Jun 5;13(1):99-112. doi: 10.1159/000531377. eCollection 2024 Feb.
2
Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH).仑伐替尼联合经动脉化疗栓塞术作为晚期肝细胞癌一线治疗的III期随机临床试验（LAUNCH）
J Clin Oncol. 2023 Jan 1;41(1):117-127. doi: 10.1200/JCO.22.00392. Epub 2022 Aug 3.
3
The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors.抗血管生成药物仑伐替尼诱导肝癌肿瘤血管正常化并增强放射敏感性。
Med Oncol. 2021 Apr 21;38(6):60. doi: 10.1007/s12032-021-01503-z.
4
Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.动脉肿瘤灌注的变化是不可切除肝细胞癌患者仑伐替尼疗效的早期生物标志物。
World J Gastroenterol. 2019 May 21;25(19):2365-2372. doi: 10.3748/wjg.v25.i19.2365.
5
Quantification of hepatic parenchymal blood flow by contrast ultrasonography with flash-replenishment imaging.通过使用快速补充成像的超声造影对肝实质血流进行定量分析。
Ultrasound Med Biol. 2006 Oct;32(10):1459-66. doi: 10.1016/j.ultrasmedbio.2006.06.004.
6
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.肿瘤血管正常化：抗血管生成治疗中的一个新兴概念。
Science. 2005 Jan 7;307(5706):58-62. doi: 10.1126/science.1104819.